TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03761225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04026711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinol
Description: Mitoquinol (MitoQ) 40 mg per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo daily for 12 weeks
Study: NCT01739764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
Study: NCT02862132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Study: NCT02781376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA OSA
Description: Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Snoring Identification Only
Description: Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
Study: NCT00437372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
Study: NCT03886389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP
Description: Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
Study: NCT01980745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate 250mg
Description: Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03752060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
Study: NCT01807221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02634944

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)
Study: NCT04457934

Intervention type: DRUG
Intervention: Plenvu
Description: All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines

Intervention type: DRUG
Intervention: Plenvu
Description: All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
Study: NCT03107533

Intervention type: OTHER
Intervention: Video recording of clinical visit
Description: For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
Study: NCT00842777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent manualized group treatment
Description: Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent self-help groups
Description: Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
Study: NCT02981563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Together
Description: For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
Study: NCT02420483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation chest compressions
Study: NCT00123682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proactive outreach to counseling
Description: Project staff reach out to engage referred smoker into telephone counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proactive outreach to counseling
Description: Project staff reach out to engage referred smoker into telephone counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reactive outreach to counseling
Description: Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reactive outreach to counseling
Description: Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Description: Multi-session telephone counseling, delivered by California Smokers' Helpline
Study: NCT01807221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspra (eplerenone)
Study: NCT03545113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper arm arteriovenous graft surgery
Description: Creation of arteriovenous graft vascular access for hemodialysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arm arteriovenous fistula surgery
Description: Creation of arteriovenous fistula vascular access for hemodialysis
Study: NCT01735357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-rich triacylglycerol oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - olive oil (BP specification)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich triacylglycerol oil
Study: NCT02313818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
Study: NCT01727518

Intervention type: OTHER
Intervention: As the LEAD study is an observational cohort study, there is no intervention to report.
Description: As the LEAD study is an observational cohort study, there is no intervention to report.
Study: NCT03117465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the experimental group
Description: Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.

Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
Study: NCT03326089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
Study: NCT01749163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GIP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Study: NCT04228406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG161
Description: There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
Study: NCT00578578

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: eicosapentaenoic acid (EPA),
Description: three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: eicosapentaenoic acid (EPA),
Description: three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
Study: NCT03000348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule
Study: NCT03882671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiTel Epilog
Description: EEG recording device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empatica E4
Description: PPG, sweat level, temperature and accelerometry recording device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENEActiv
Description: Temperature, light level and accelerometry recording device
Study: NCT04861662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft procedure
Description: Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
Study: NCT04176133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Study: NCT03000348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine
Description: Oral Cysteamine Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule
Study: NCT04281693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard screening strategy
Description: The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New screening strategy
Description: The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
Study: NCT03112408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forward adaptation of reactive saccades
Description: Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward adaptation of reactive saccades
Description: Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward adaptation of reactive saccades
Description: Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Execution of reactive saccades
Description: Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generation of reactive saccades
Description: Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
Study: NCT00878553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP-1041 (experimental formulation of zaleplon)
Description: tablet at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP-1041 (experimental formulation of zaleplon)
Description: tablet at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP-1041 (experimental formulation of zaleplon)
Description: tablet at bedtime
Study: NCT00626015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3-KLH conjugate vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3-KLH conjugate vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: Given IV
Study: NCT00123682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Description: Multi-session telephone counseling, delivered by California Smokers' Helpline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-help
Description: Project staff send out self-help materials for smoking cessation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-help
Description: Project staff send out self-help materials for smoking cessation
Study: NCT01587625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT03085771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desferal
Description: It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Study: NCT03942003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhomboid blocks
Description: Rhomboid nerve block was performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC blocks
Description: PEC I-II blocks was performed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control groups
Description: Infiltration analgesia was performed
Study: NCT04231968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo of AK0529
Description: The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Study: NCT02440854

Intervention type: DRUG
Intervention: afatinib
Description: Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
Study: NCT02503644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA337
Description: Capsules of 200mg IVA337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA337
Description: Capsules of 200mg IVA337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules without active substance
Study: NCT04129775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-413
Description: Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study: NCT04790097

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost
Description: 78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide
Study: NCT02483572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
Study: NCT03526055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study: NCT04176133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
Study: NCT03526055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study: NCT04582565

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic therapy (DLT)
Description: Manual lymphatic drainage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care